nach oben

The European Journal of Health Economics

Erschienen in:

01.12.2013 | Original Paper

Treatment costs of attention deficit hyperactivity disorder in Germany

verfasst von: Sebastian Braun, Jan Zeidler, Roland Linder, Susanne Engel, Frank Verheyen, Wolfgang Greiner

Erschienen in: The European Journal of Health Economics | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Attention deficit hyperactivity disorder (ADHD) is one of the most common behavioural disorders among children and adolescents. The number of patients as well as prescriptions to treat this disease has continuously increased over the past few years. The aim of the present study was to analyse the costs for treating ADHD patients from the perspective of a major German health insurance fund.

Methodology

Anonymised administrative claims data were available for the study. All services reimbursed by the health fund for the selected ADHD patients were recorded. Apart from the resource use attributed directly to ADHD, co-morbidities as well as incremental costs were described based on a control group design.

Results

A total of 30,264 ADHD patients were diagnosed in 2008. The total costs for these patients were €3,888, and the incremental costs were €2,902. The largest proportions of incremental costs were due to therapeutic devices and remedies like occupational therapy amounting to €1,270. Proportionate costs of €263 have been settled for pharmacotherapy with Methylphenidate and Atomoxetine. However, 41 % of the patients were not treated with ADHD-related pharmaceuticals.

Conclusions

ADHD costs are relevant from health insurance perspective. The expenses for occupational therapy constitute the cost driver. Compared to the findings of studies from the United States and contrarily to the backdrop of public discussions about considerably increased prescriptions of ADHD-specific drugs, the significantly higher additional expenses for occupational therapy services are impressing. This kind of therapy is internationally rather unknown and is therefore not acknowledged as a therapeutic standard.

Arbeitsgemeinschaft ADHS der Kinder- und Jugendärzte e.V. (Hrsg.) [ADHD Association of Paediatricians and Adolescent Medical Doctors, registered association (publisher)]. ADHS bei Kindern und Jugendlichen (Aufmerksamkeits-Defizit-Hyperaktivitäts-Störung) - Leitlinie der Arbeitsgemeinschaft ADHS der Kinder- und Jugendärzte e.V [ADHD in Children and Adolescents (Attention Deficit Hyperactivity Disorder)––Guideline of the ADHD Association of Paediatricians and Adolescent Medical Doctors, registered association]. Updated Version January (2007)

Alm B. ADHS bei Erwachsenen: Wenn Zappelphilipp erwachsen wird. [ADHD in Adults: If Fidgeting Will Develop.] Dtsch Med Wochenschr (2009); 134, Nr. 24

ABDA (Hrsg. [publisher]) – Bundesvereinigung Deutscher Apothekerverbände: Pressemitteilung 30. März (2009). [Federal Union of German Associations of Pharmacists: Press Release 30th March (2009)]. www.abda.de [Download 22/07/2011]

Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen [Advisory Council on the Assessment of Developments in the Health Care System]. Gutachten 2009 des Sachverständigenrates zur Begutachtung der Entwicklung im Gesundheitswesen - Koordination und Integration Gesundheitsversorgung in einer Gesellschaft des längeren Lebens [Report 2009 of the Advisory Council on the Assessment of Developments in the Health Care System––Coordination and Integration––Health Care in an Ageing Society]. Köln: Bundesanzeiger Verlag (2009)

Schöffski, O., Sohn, S., Happich, M.: Die gesamtgesellschaftliche belastung durch die hyperkinetische störung (HKS) bzw. Aufmerksamkeitsdefizit-/hyperaktivitätsstörung (ADHS). Gesundheitswesen 70, 398–403 (2008)CrossRefPubMed

Wehmeier, P.M., Schacht, A., Rothenberger, A.: Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years. Child. Adolesc. Psychiatr. Mental. Health. 3, 3 (2009). doi:10.1186/1753-2000-3-3 CrossRef

Schöffski, O.: Grundformen gesundheitsökonomischer evaluationen [Basic forms of health economic evaluations]. In: Schöffski, O., von der Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen, 3rd edn, pp. 65–94. Springer, Berlin (2007)CrossRef

Greiner, W., Schöffski, O.: Grundprinzipien einer wirtschaftlichkeitsuntersuchung [Basic principles of economic studies]. In: Schöffski, O., von der Schulenburg, J.M. (eds.) Gesundheitsökonomische Evaluationen, 3rd edn, pp. 167–191. Springer, Berlin (2007)

Ärzteblatt (Hrsg. [publisher]). G-BA: ADHS-Medikamente auch für Erwachsene [Joint Federal Committee: ADHD Medication for Adults as Well]. Available at URL: http://www.aerzteblatt.de/nachrichten/46378/G-BA_ADHS-Medikamente_auch_fuer_Erwachsene.htm [Download 19/07/2011]

10.

Holle, R., Behrend, C., Reitmeir, P., John, J.: Methodenfragen der Nutzung von GKV-Routinedaten für kostenanalysen [Methodological questions on the use of SHI routine data for cost analyses]. In: Swart, E., Ihle, P. (eds.) Routinedaten im Gesundheitswesen: Grundlagen, Methoden und Perspektiven, pp. 301–318. Huber, Bern (2005)

11.

Prenzler A, Zeidler J, Braun S, von der Schulenburg JM. Bewertung von Ressourcen im Gesundheitswesen aus der Perspektive der deutschen Sozialversicherung [Assessment of health care resources from the viewpoint of the German social insurance]. PharmacoEconomics––German Research Articles 2010; 8(1): 47–66

12.

Kassenärztliche Bundesvereinigung (Hrsg.)]National Association of Statutory Health Insurance Physicians (publisher)]. Beschluss des erweiterten Bewertungsausschusses gemäß §87 Abs. 4 SGB V in seiner Sitzung am 23. Oktober 2008 zur Anpassung des Einheitlichen Bewertungsmaßstabs (EBM) sowie zur Neuordnung der vertragsärztlichen Vergütung im Jahr 2009 [Decision of the Extended Valuation Committee Pursuant To Section 87 Paragraph 4 SGB V [Social Security Code V] in its meeting on 23rd October 2008 on the Adjustment of the Uniform Value Scale as well as the Reorganisation of Remunerating SHI Physicians in 2009] Available at URL: http://www.kbv.de/8157.html [Download 19/07/2011]

13.

Guevara, J., Lozano, P., Wickizer, T., Mell, L., Gephart, H.: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 108, 71–78 (2001)CrossRefPubMed

14.

Leibson, C.L., Katusic, S.K., Barbaresi, W.J., Ransom, J., O’Brien, P.C.: Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 285(1), 60–66 (2001)CrossRefPubMed

15.

Chan, E., Zhan, C., Homer, C.J.: Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. 156, 504–511 (2002)CrossRefPubMed

16.

Burd, L., Klug, M.G., Coumbe, M.J., Kerbeshian, J.: Children and adolescents with attention deficit-hyperactivity disorder: 1. prevalence and cost of care. J. Child Neurol. 18, 555–561 (2003)CrossRefPubMed

17.

Leibson, C.L., Long, K.H.: Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmacoeconomics 21, 1239–1262 (2003)CrossRefPubMed

18.

Swensen, A.R., Birnbaum, H.G., Secnik, K., Marynchenko, M., Greenberg, P., Claxton, A.: Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J. Am. Acad. Child Adolesc. Psychiatr. 42(12), 1415–1423 (2003)CrossRef

19.

Birnbaum, H.G., Kessler, R.C., Lowe, S.W., Secnik, K., Greenberg, P.E., Leong, S.A., Swensen, A.R.: Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr. Med. Res. Opin. 21(2), 195–205 (2005)CrossRefPubMed

20.

Matza, L.S., Paramore, C., Prasad, M.: A review of the economic burden of ADHD. Cost. Eff. Resour. Alloc. 3, 5 (2005). doi:10.1186/1478-7547-3-5 PubMedCentralCrossRefPubMed

21.

Ray, T.G., Levine, P., Croen, L.A., Bokhari, F.A.S., Hu, T.W., Habel, L.A.: Attention-deficit/hyperactivity disorder in children- excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch. Pediatr. Adolesc 160, 1063–1069 (2006)CrossRef

22.

Pelham, W.E., Foster, M.E., Robb, J.A.: The economic impact of attention deficit/hyperactivity disorder in children and adolescents. J. Pediatr. Psychol. 32(6), 711–727 (2007)CrossRefPubMed

23.

Schlander, M., Trott, G.E., Schwarz, O.: Gesundheitsökonomie der aufmerksamkeitsdefizit-/hyperaktivitätsstörung in Deutschland -Teil 1: Versorgungsepidemiologie und krankheitskosten [The health economics of attention deficit hyperactivity disorder in germany. part 1: health care utilization and cost of illness]. Nervenarzt 81(3), 289–300 (2010)CrossRefPubMed

24.

Gebhardt B, Finne E, von Rahden O, Kolip P, Glaeske G, Würdemann E. ADHS bei Kindern und Jugendlichen––Befragungsergebnisse und Auswertungen von Daten der Gmünder ErsatzKasse [ADHD in Children and Adolescents––Survey Results and Evaluation of Data of the Gmünder ErsatzKasse]. Schriftenreihe zur Gesundheitsanalyse, Band 65. St. Augustin: Asgard-Verlag (2008)

25.

Ruof, J., Hülsemann, J.L., Mittendorf, T., Handelmann, S., von der Schulenburg, J.M., Zeidler, H., Merkesdal, S.: Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources. Ann. Rheum. Dis. 62(6), 544–549 (2003)PubMedCentralCrossRefPubMed

26.

Wu, E., Chen, L., Birnbaum, H., Yang, E., Cifaldi, M.: Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr. Med. Res. Opin. 23(8), 1749–1759 (2007)CrossRefPubMed

Titel: Treatment costs of attention deficit hyperactivity disorder in Germany
verfasst von: Sebastian Braun
Jan Zeidler
Roland Linder
Susanne Engel
Frank Verheyen
Wolfgang Greiner
Publikationsdatum: 01.12.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 6/2013
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-012-0440-5

Springer Medizin

Abstract

Background

Methodology

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation

Long-term health investment when people underestimate their adaptation to old age-related health problems

Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial

The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies

The impact of generic reference pricing in Italy, a decade on